key: cord-0956303-6i7cofc8
authors: Dai, Cong; Jiang, Min; Huang, Yu-hong
title: The associations between pharmacological gastric acid suppression and adverse outcomes in patients with COVID-19
date: 2021-03-09
journal: Gastroenterology
DOI: 10.1053/j.gastro.2021.03.012
sha: c7e03360c5d81299a308c3c8a8dde27250c5b90d
doc_id: 956303
cord_uid: 6i7cofc8

nan

We read with interest the article by Faisal Kamal et al evaluating the association between famotidine or PPI use and outcomes in patients with COVID-19 by a meta-analysis 1 . The author found that there is lack of consistent associations between pharmacological gastric acid suppression (famotidine and PPI) and adverse outcomes in patients with COVID-19.

Because their findings are important to both current practice and future research, several questions deserve attention.

First, most of the included studies offer limited information on the type, dose, frequency, duration, concomitant therapy, as well as indication related to PPI treatment. The effect estimates presented by PPI or famotidine dose and duration of use show surprising variability that are not explained by the included studies. Some studies found that once daily PPI use for >6 months should have a significantly smaller effect than once daily PPI use of <6 months in patients with COVID-19. PPI twice daily for <6 months was no different than once daily PPI in patients with COVID-19, whereas the same dose for >6 months had a significantly larger effect than once daily dosing. Because there is no tachyphylaxis with PPI and steady state is achieved in 5-7 days, the effects of acid control should be consistent across the presented durations of PPI use. The lack of consistency of the results based on dose and duration of PPI use is troubling.

The increase in gastric pH may indeed be beneficial to SARS-CoV-2, but this is theoretical and not proven. Both PPI and H2 blockers such as famotidine can elevate gastric pH. But some studies found that once daily H2 blockers were associated with a significant decreased risk of COVID-19. It is unexplained why PPI and H2 blockers have opposite effects.

Second, most of the studies are retrospective observational cohorts that are prone to bias even after apparently appropriate adjustments. The potential explanation for an apparent association between PPI and adverse outcomes in patients with COVID-19 is 'channelling bias'. Channelling bias refers to the tendency of clinicians to prescribe certain medications to patients with more severe underlying illness. Therefore, the use of certain medications does not truly predispose individuals to develop specific diseases, but rather falsely gives the appearance of an association because patients with certain diseases are more likely to be taking the medication in question. In short, channelling bias leads to 'guilt by association' rather than a true 'cause and effect' relationship. So, it is quite possible that patients with J o u r n a l P r e -p r o o f more severe COVID-19 are more likely to receive PPI therapy than individuals with less severe COVID-19 or fewer comorbid illnesses. For example, PPI is a part of a standard supportive care in the most severe patients or intubated patients with COVID-19. At the same time, the proportion of diabetes, hypertension and heart failure in PPI users are also significantly higher than those in PPI nonusers. Data regarding relevant comorbidities of the study groups (e.g., hypertension, cardiovascular disease, diabetes, chronic respiratory and kidney disease) are importantly absent leading to higher likelihood of confounding.

In conclusion, the methodologic issues and result inconsistencies remain regarding PPI or famotidine and the outcomes of COVID-19. Although we have no argument with any recommendation to use PPI or famotidine required for patients with COVID-19, we are concerned that these data will result in needless anxiety and perhaps discontinuation of PPI or famotidine in patients with COVID-19 who need them for appropriate clinical indications.

And discontinuation of PPI or famotidine in some patients with COVID-19 can be associated with significant risk of harm. In the future, well-controlled prospective studies are needed to provide more solid evidence on this topic as the discovery of either detrimental or beneficial effects of PPI or famotidine in patients with COVID-19 will likely affect guidelines and clinical decision making given the current widespread use of these drugs.

Lack of consistent associations between pharmacological gastric acid suppression and adverse outcomes in patients with COVID-19: meta-analysis of observational studies